Search results for " Color"

showing 10 items of 770 documents

Combined aortic and mitral stenosis in mucopolysaccharidosis type I-S (Ullrich-Scheie syndrome)

1999

The genetic mucopolysaccharidosis syndromes (MPS) are autosomal recessive inborn errors of metabolism. Heart valve involvement in MPS is not uncommon but only a few case reports of successful cardiac surgery are available. In particular, reports of combined aortic and mitral stenosis associated with MPS type I-S are very rare. Both type I and type VI MPS are associated with significant left sided valvar heart disease that requires surgical valve replacement because of irregular valve thickening, fibrosis, and calcification. A 35 year old man had severe mitral valve stenosis after successful surgical replacement of a stenotic aortic valve. Valvar heart disease was investigated by cardiac ult…

AdultMaleAortic valvecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyMucopolysaccharidosis Imedicine.medical_treatmentCase ReportMitral valve stenosisValve replacementMitral valveInternal medicineMucopolysaccharidosis IHumansMitral Valve StenosisMedicinecardiovascular diseasesHeart valvebusiness.industrynutritional and metabolic diseasesAortic Valve Stenosismedicine.diseaseEchocardiography Doppler ColorCardiac surgerySurgerymedicine.anatomical_structureEchocardiographyAortic valve stenosiscardiovascular systemCardiologyMitral ValveCardiology and Cardiovascular MedicinebusinessHeart
researchProduct

Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses

1995

In echocardiographic and necropsy studies nodular thickening of the mitral valve and, less frequently, of the aortic valve has been found in 60%-90% of patients with mucopolysaccharidoses (MPS). Little is known about the haemodynamic consequences of these morphological changes. In this study 84 unselected patients with different enzymatically proven MPS and 84 age and sex matched, healthy persons were studied prospectively by colour Doppler flow mapping. The patients' age ranged from 1 to 47 years (median 8.1 years). Mitral and aortic regurgitation were defined as a holosystolic or holodiastolic jet originating from the valve into the left atrium or the left ventricular outflow tract, respe…

AdultMaleAortic valvemedicine.medical_specialtyAdolescentAortic Valve InsufficiencyHemodynamicsRegurgitation (circulation)Doppler echocardiographyMitral valveInternal medicinemedicineHumansVentricular outflow tractProspective Studiescardiovascular diseasesChildskin and connective tissue diseasesMitral regurgitationmedicine.diagnostic_testbusiness.industryInfantMitral Valve InsufficiencyMiddle AgedMucopolysaccharidosesEchocardiography Doppler ColorSurgerymedicine.anatomical_structureChild PreschoolPediatrics Perinatology and Child Healthcardiovascular systemCardiologyFemaleComplicationbusinessEuropean Journal of Pediatrics
researchProduct

RUPTURE OF A LEFT SINUS OF VALSALVA ANEURYSM INTO THE PULMONARY ARTERY.

2006

Sinus of Valsalva aneurysm is a rare congenital defect and the diagnosis is usually made after it ruptures. Very few cases of non-complicated sinus of Valsalva aneurysm have been published. The anomaly most often involves the right coronary sinus and less frequently the non-coronary sinus. A case with left sinus of Valsalva has not been reported. Since the aortic valve occupies a central position in the base of the heart, rupture of a sinus of Valsalva aneurysm can occur in any of the four heart chambers. Rupture into the pulmonary artery is very rare and is mostly associated with other congenital cardiopathies. ª 2005 The European Society of Cardiology. Published by Elsevier Ltd. All right…

AdultMaleAortic valvemedicine.medical_specialtyHeart.chambersAneurysm RupturedPulmonary ArteryMyocardial ruptureDiagnosis DifferentialAneurysmInternal medicinemedicine.arteryHIV Seropositivityotorhinolaryngologic diseasesHumansMedicineRadiology Nuclear Medicine and imagingcardiovascular diseasesHeart AneurysmSinus (anatomy)Coronary sinusbusiness.industryGeneral MedicineSinus of Valsalvamedicine.diseaseAneurysmEchocardiography Doppler Colorbody regionsmedicine.anatomical_structurePulmonary arterycardiovascular systemCardiologyCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiologyRupture into the pulmonary artery
researchProduct

Early stage human colorectal cancer: prognostic value of nm23-H1 protein overexpression

1997

Nm23 gene codifies for a nucleoside diphosphate kinase allowing the intracellular transduction of the signals. In colorectal cancer nm23 protein expression seems related to the progression of the disease. By immunohistochemistry we have studied the intracytoplasmatic nm23 H1 protein expression in 20 patients affected by colorectal cancer at initial stage. In 12 cases it resulted elevated and in four the disease recurred. The overexpression was not correlated with other prognostic factors. Nm23 H1-positive patients affected by colorectal cancer at initial stage could be considered at risk for disease recurrence and included in a more frequent follow-up protocol.

AdultMaleCancer ResearchPathologymedicine.medical_specialtyColorectal cancerRectumDiseaseMouse model of colorectal and intestinal cancerGene expressionBiomarkers TumormedicineCarcinomaHumansAgedMonomeric GTP-Binding ProteinsNeoplasm StagingAged 80 and overbusiness.industryMiddle AgedNM23 Nucleoside Diphosphate KinasesPrognosismedicine.diseaseNucleoside-diphosphate kinaseNeoplasm Proteinsmedicine.anatomical_structureOncologyNucleoside-Diphosphate KinaseDisease ProgressionCancer researchImmunohistochemistryFemaleColorectal NeoplasmsbusinessTranscription FactorsCancer Letters
researchProduct

Clinical relevance of thymidylate syntetase expression in the signet ring cell histotype component of colorectal carcinoma

2004

Thymidylate Synthase (TS) is the key enzyme for DNA synthesis pathways and is inhibited by 5-fluorouracil (5FU). The aim of this work was to study TS expression and the proliferation rate in the different histological types of colorectal carcinoma (CRC). 50 patients with CRC were included in this study and evaluated immunohistochemically using the monoclonal antibodies, TS106 and Ki67. 20 tumours were of the intestinal type, 15 cases were signet ring cell carcinoma (SRCCs) and 15 cases were "mixed-type", with at least two different histological components. Intestinal and mucinous histotypes were positive for TS and Ki67, while "signet ring cell" samples were negative or showed only weak and…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyProliferation indexColorectal cancerSettore MED/08 - Anatomia PatologicaThymidylate synthase expressionThymidylate synthaseSignet ring cell carcinomaSignet ring cell carcinomaCarcinomamedicineHumansThymidylate synthase expression; Signet ring cell carcinoma; Colorectal carcinoma; ImmunohistochemistryAgedbiologySignet ring cellThymidylate SynthaseMiddle AgedCell cyclemedicine.diseaseImmunohistochemistrydigestive system diseasesNeoplasm ProteinsColorectal carcinomaKi-67 AntigenOncologybiology.proteinCancer researchSettore BIO/14 - FarmacologiaImmunohistochemistryFemaleColorectal NeoplasmsCarcinoma Signet Ring Cell
researchProduct

Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorecta…

2009

BACKGROUND: The aim of the current study was the investigation of the value of bevacizumab + 5-fluorouracil(5–FU)/folinic acid in patients with advanced colorectal cancers who have exhausted standard chemotherapy options. METHODS: The authors included 48 heavily pretreated patients (colon:rectum, 33:15; men:women, 23:25; median age, 63 years; range, 27-79 years) whose disease had progressed during or within an oxaliplatin-based first-line chemotherapy, an irinotecan-based second-line regimen, and a third-line treatment with cetuximab plus weekly irinotecan. Bevacizumab was given at a dose of 5 mg/kg. 5-FU/folinic acid was administered according to the de Gramont schedule. RESULTS: The respo…

AdultMaleCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancerSettore MED/06 - Oncologia MedicaLeucovorinCetuximabAntibodies Monoclonal HumanizedGastroenterologyDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedCetuximabbusiness.industryCancerAntibodies MonoclonalMiddle Agedmedicine.diseaseSurgeryOxaliplatinIrinotecanBevacizumabRegimenBevacizumabcolorectal cancerOncologyDrug Resistance NeoplasmRetreatmentFemaleFluorouracilbusinessBevacizumab; Colorectal cancer; cancer combination chemotherapyColorectal Neoplasmsmedicine.drug
researchProduct

Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study

2005

The aims of this multicentre, randomised phase III trial were to evaluate: (1) the role of levamisol (LEV); and (2) the role of folinic acid (FA), added to 5-fluorouracil (5FU) in the adjuvant treatment of colorectal cancer. Patients with histologically proven, radically resected stage II or III colon or rectal cancer were eligible. The study had a 2x2 factorial design with four treatment arms: (a) 5FU alone, (b) 5FU+LEV, (c) 5FU+FA, (d) 5FU+LEV+FA, and two planned comparisons, testing the role of LEV and of FA, respectively. From March 1991, to September 1998, 1327 patients were randomised. None of the two comparisons resulted in a significant disease-free (DFS) or overall (OAS) survival a…

AdultMaleCancer Researchmedicine.medical_specialtyRandomization5-fluorouracil modulation; adjuvant chemotherapy; colorectal cancermedicine.drug_classColorectal cancerLeucovorincolorectal cancerAntimetaboliteGastroenterologyDisease-Free SurvivalFolinic acidRECTAL CANCER5-fluorouracil modulationCOLONInternal medicineClinical StudiesAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansAgedbusiness.industryHazard ratioMiddle Agedmedicine.diseaseSurgeryadjuvant chemotherapyTreatment OutcomeLevamisoleOncologyChemotherapy AdjuvantFluorouracilVomitingFemaleFluorouracilmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugBritish Journal of Cancer
researchProduct

Color-coded duplex ultrasonography of the origin of the vertebral artery: normal values of flow velocities.

2000

The introduction of color-coded duplex ultrasonography has improved the ease of performing ultrasound investigations of the vertebral arteries. So far, normal values of flow velocities have been reported only for the intertransverse region of the vertebral artery (V2 segments). Atherosclerotic disease at the origin of the vertebral arteries (V0 segment) is frequent and is one of the risk factors for vertebrobasilar ischemic disease. Normal values of flow velocities of the vertebral artery origin are needed to assess pathologic findings, such as vertebral artery origin stenosis or dissection. The aim of this study was to describe the normal flow velocities of vertebral artery origin (V0 segm…

AdultMaleDuplex ultrasonographyVertebral arteryIschemiaDissection (medical)Statistics NonparametricReference Valuesmedicine.arterymedicineHumansRadiology Nuclear Medicine and imagingUltrasonography Doppler ColorVertebral ArteryAgedAged 80 and overUltrasonography Doppler Duplexbusiness.industryUltrasoundAnatomyNomogramMiddle Agedmedicine.diseaseStenosisDuplex (building)FemaleNeurology (clinical)businessBlood Flow VelocityJournal of neuroimaging : official journal of the American Society of Neuroimaging
researchProduct

Influence of stimulus color on the control of reaching-grasping movements.

2001

This kinematic study aimed to determine whether color is a stimulus property involved in the control of reaching-grasping movements. Subjects reached and grasped a target-object, located either on the right or on the left of the subject's midline. A distractor, placed along the subject's midline, could be randomly presented. The colors, i.e., both chromaticity (red and green stimuli were presented) and lightness, of the target and distractor were varied in experiment 1. Only stimulus lightness and only stimulus chromaticity were varied in experiments 2 and 3, respectively. In experiment 4 subjects matched with their thumb and index finger the size of the target-stimuli presented in experime…

AdultMaleHuman kinematicsProperty (programming)MovementKinematicsStimulus (physiology)Neuropsychological TestsTarget colorOpticsOrientationmedicineReaction TimeHumansComputer visionChromaticity and lightnessChromaticityHand Strengthbusiness.industryGeneral NeuroscienceGRASPMotor controlReaching-graspingBody movementIndex fingerBiomechanical Phenomenamedicine.anatomical_structurePattern Recognition VisualSpace PerceptionArmFemaleArtificial intelligencebusinessPsychologyInterferenceReaching-grasping · Human kinematics · Target color · Chromaticity and lightness · InterferenceColor PerceptionPhotic StimulationPsychomotor PerformanceExperimental brain research
researchProduct

Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a p…

2008

This is a phase II institutional exploratory trial of biweekly irinotecan and cetuximab administration regimen in metastatic colorectal cancer patients progressing to at least one previous chemotherapy line. A total of 40 patients were treated between November 2005 and November 2007 with irinotecan 180 mg m−2 and cetuximab 500 mg m−2 q2w (every 2 weeks), in every 21-day cycles, until unacceptable toxicity or progressive disease. An overall response rate of 22.5% was obtained (two complete and seven partial responses). The disease control rate was 60%. The time to progression was 3.4 months and the overall survival was 8 months. The toxicity compared very favourably to weekly cetuximab combi…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentCetuximabAntibodies Monoclonal HumanizedIrinotecanDrug Administration ScheduleInternal medicineAntineoplastic Combined Chemotherapy ProtocolsClinical StudiesmedicineHumansProspective StudiesNeoplasm MetastasisAdverse effectAgedChemotherapyCetuximabbusiness.industrymetastatic colorectal cancerbiweekly scheduleAntibodies MonoclonalMiddle Agedmedicine.diseaseSurgeryClinical trialIrinotecanRegimenOncologyCamptothecinFemaleColorectal NeoplasmsbusinessProgressive diseasemedicine.drugBritish Journal of Cancer
researchProduct